Post by
Jon9800 on Jun 21, 2022 10:28am
$HMTXF to issue the global field use license of NCP-01 to Pr
Hemostemix will grant PreCerv a global field of use licence for NCP-01 and its autologous stem cell technology to treat central and peripheral nervous system diseases. Such as Neuropathic pain syndrome, traumatic spinal cord injury, etc.